Skip to Main Content
Acronyms and Ab..
++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
17-AAG 17-allylamino-17-demethoxy-geldanamycin
4HPR N-4-hydroxyphenyl
5-FU fluorouracil
5'-DFUR 5'-deoxy-5-fluorouridine
ACOSOG American College of Surgeons Oncology Group
ADC antibody-drug conjugate
ADCC antibody-dependent cell-mediated cytotoxicity
ADH atypical ductal hyperplasia
AI aromatase inhibitor
AJCC American Joint Committee on Cancer
ALDH1 aldehyde dehydrogenase 1
ALH atypical lobular hyperplasia
ALK anaplastic lymphoma kinase
ALTTO Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation
AMP adenosine monophosphate
APHINITY Adjuvant Pertuzumab and Herceptin IN Initial TherapY of Breast Cancer
ASCO American Society of Clinical Oncology
ATP adenosine triphosphate
AVADO Avastin And Docetaxel
AVEREL AVastin in combination with hERceptin/docetaxEL in HER2-positive metastatic breast cancer
BMD bone mineral density
BOLERO Breast cancer trials of OraL EveROlimus
CAP College of American Pathologists
CES-D Center for Epidemiologic Studies Depression Scale
CHD coronary heart disease
CI confidence interval
CLEOPATRA CLinical Evaluation Of Pertuzumab And TRAstuzumab
CLSI Clinical and Laboratory Standard Institute
CNA copy number alterations
CNS central nervous system
COE Center of Excellence
CORE Continuing Outcomes Relevant to Evista
COX Cyclooxygenase
CTL cytotoxic T lymphocyte
DAB 3,3'-diaminobenzidine
DCIS ductal carcinoma in situ
dCK deoxycytidine kinase
dFdCMP fluourodeoxycytidine monophosphate
dFdCTP 2'-2'-difluourodeoxycytidine triphosphate
DFS disease-free survival
DHFR dihydrolate reductase
DPYD dihydropyrimidine dehydrogenase
DVT deep vein thrombosis
EGFR epidermal growth factor receptor
EMILIA An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
EMT epithelial-mesenchymal transition
ER estrogen receptor
ERK1/2 extracellular signal regulated kinase
FDA Food and Drug Administration
FDR false discovery rate
FdUMP fluorodeoxyuridine monophosphate
FFPE formalin-fixed paraffin embedded
FISH fluorescent in situ hybridization
FUTP fluorouridine triphosphate
GM-CSF granulocyte macrophage colony-stimulating factor
GO gene ontology
GSEA gene set enrichment analysis
GST glutathione S-transferase
GWAS genome-wide association study
hCNT human concentrative transporter
hENT human equilibrative transporter
HER human epidermal growth factor receptor
hNT human nucleotide transporter
HOT HRT Opposed to low-dose Tamoxifen
HR hazard ratio
Hsp90 heat shock protein 90
IBIS International Breast Cancer Intervention Study
IGF-1 insulin-like growth factor 1
IgG immunoglobulin G
IHC Immunohistochemical
LCIS lobular carcinoma in situ
LDL low-density lipoprotein
mAb monoclonal antibody
MARIANNE A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer
MEK1/2 mitogen-activated extracellular-signal regulated kinase
MINDACT Microarray In Node-negative and 1-3 node positive Disease may Avoid ChemoTherapy
MORE Multiple Outcomes of Raloxifene Evaluation
MOS Medical Outcomes Study
NCI National Cancer Institute
NCIC-CTG National Cancer Institute of Canada Clinical Trials Group
NeoALTTO Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation
NSABP National Surgical Adjuvant Breast and Bowel Project
OR odds ratio
OS overall survival
PAM prediction analysis of microarrays
pCR pathologic complete response
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PDK1 phosphoinositide-dependent kinase 1
PE pulmonary embolism
PEARL Postmenopausal Evaluation and Risk-reduction with Lasofoxifene
PEPI preoperative endocrine prognostic index
PET positron emission tomography
PFS progression-free survival
PIP2 phosphatidylinositol 4,5-diphosphate
PIP3 phosphatidylinositol 3,4,5-triphosphate
pNR pathologic no response
pPR pathologic partial response
PR progesterone receptor
PTEN phosphatase and tensin homolog
QA quality assurance
QOL quality of life
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
RCB residual cancer burden
ROR risk of recurrence
RR relative risk
RUTH Raloxifene Use for the Heart
SAM significance analysis of microarrays
SERM selective estrogen receptor modulator
SF-36 Short Form Health Survey
SNP single nucleotide polymorphism
STAR Study of Tamoxifen and Raloxifene
TAILOR x Trial Assigning IndividuaLized Options for Treatment (Rx)
T-DM1 trastuzumab-DM1
TEACH Tykerb Evaluation After Chemotherapy
TIA transient ischemic attack
TNBC triple-negative breast cancer
TOP2A topoisomerase II alpha
TRYPHAENA Trastuzumab plus Pertuzumab in Neoadjuvant HER2-Positive Breast Cancer
TTP time to progression
TYMP thymidine phosphorylase
TYMS thymidylate synthase
VEGF vascular endothelial growth factor
WG-DASL Whole Genome cDNA-mediated Annealing, Selection extension and Ligation

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.